HYDROHEAL Multi-functional hydrogels for promoting bone fracture healing through local induced release of pharmaceutical agents and gradual matrix replacement by the regenerating bone
- Coordinator
- Universitat Politecnica De Valencia, Spain
- Runs
- 1 June 2025 to 31 May 2029
- Status
- Running
- EU funding
- €6.5m
- Total cost
- —
- Partners
- 13 organisations in 7 countries
- Type
- Innovation Action
- Grant agreement
- 101178398
What the project is doing
In the project's own words, from its summary on CORDIS.
Bone atrophy and fractures, resulting from trauma, infections, osteoporosis, or cancer, are global health concerns. Standard care with cement and bone grafts has limitations. Synthetic polymers like polymethyl methacrylate risk leakage, spinal issues, and poor healing. Donor shortages for allogenic bone grafting and invasive procedures pose risks such as rejection and viral transmission. HYDROHEAL innovates with hydrogel formulations to address bone strength challenges by treating vertebral and alveolar fractures.
HYDROHEAL aims to develop safe, sustainable scaling, and cost-effective formulations using renewable biomaterials for targeted drug delivery, aligning closely with the EU Circular Economy Action Plan and Chemicals Strategy for Sustainability. It is ready to introduce a new era in fracture therapy. The proposed self-solidifying hydrogels release active pharmaceutical ingredients locally upon external stimulation, potentially improving treatment efficacy, preventing infections, and speeding up fracture healing.
The objectives of the project are:1. Develop novel injectable hydrogel formulations combining natural substance derivates to enhance healing, inhibit bacterial growth, and monitor therapy progress in vivo.2. Simultaneously manufacture carriers as micro- and nano-particles, surface-functionalized to incorporate pharmaceutical agents, releaseable upon external stimuli for tailored drug release.3. Validate safe and optimized hydrogel formulations for treating vertebral and alveolar bone fractures through in vitro and in vivo tests.4.
Demonstrate scalable and sustainable biomaterial manufacturing through safe design methods, machine learning, and predictive life cycle assessment.5. Develop machine learning and hybrid digital modeling methods, combining adaptive design of experiments and physics-based modeling with advanced characterization techniques.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitat Politecnica De Valencia | Valencia | Spain | Coordinator |
| Vet Ex Machina Limited | Nicosia | Cyprus | Participant |
| Consultech Technologieberatung GmbH | Berlin | Germany | Participant |
| Asphalion SL | Barcelona | Spain | Participant |
| Sitec Pharmabio SL | Esplugues De Llobregat | Spain | Participant |
| Universitat Politecnica De Catalunya | Barcelona | Spain | Participant |
| Royal College of Surgeons in Ireland | Dublin 2 | Ireland | Participant |
| Politecnico Di Torino | Torino | Italy | Participant |
| Separeco Srl | Macello | Italy | Participant |
| Fluidinova SA | Maia | Portugal | Participant |
| Centre for Process Innovation Limited Lbg | Redcar Cleveland | United Kingdom | Participant |
| University of Newcastle Upon Tyne | Newcastle Upon Tyne | United Kingdom | Participant |
| University of Warwick | Coventry | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI